-- Data Presented at the American College of Cardiology 2010 Annual Meeting Suggests Treatment with the Neovasc Reducer Is Safe and Improves Angina Symptoms for at Least Three Years --
Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms. These three-year results build on the positive six-month data previously reported in the Journal of the American College of Cardiology.
Refractory angina is a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle. It currently affects over two million patients worldwide, who typically lead severely restricted lives, and its incidence is growing. Current treatment options are limited.
The Neovasc Reducer is a unique device that is implanted in the coronary sinus vein. The Reducer is intended to provide relief of refractory angina symptoms by modulating blood flow in the coronary sinus and thereby increasing perfusion of oxygenated blood to areas of the heart muscle were it is most needed. Implantation of the Reducer is performed using a minimally invasive percutaneous procedure that is similar to implanting a coronary stent and takes approximately 20 minutes.